Arcturus Therapeutics Holdings Inc. Q2 2026 Earnings Recap

Arcturus shares surged 18.4% as the market rewarded the regained global rights to its validated sa-mRNA vaccine platform and KOSTAIVE COVID vaccine, along with a $12 million upfront payment and removal of $16 million in liabilities. This strategic move clearly outshined ongoing development progress in rare disease programs that remain largely in clinical stages.

Key Takeaways

• Regained full global rights to KOSTAIVE COVID vaccine and broader infectious disease sa-mRNA platform, providing strategic control and commercial flexibility.
• Received $12 million cash payment from CSL Seqirus and eliminated approximately $16 million in related liabilities, positively impacting the balance sheet.
• Ongoing Phase II clinical studies for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) advancing as planned, with Phase II enrollment completed for ARCT-810; data readouts expected later this year.
• Expansion of ARCT-032 trial enrollment into Israel and Turkey to access higher prevalence patient populations with null CF mutations, potentially accelerating recruitment.
• No updates provided on financial results or near-term commercial revenue streams beyond the vaccine portfolio transaction.